Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802
Yosuke Kawashima(Sendai Kousei Hospital), Toshihiro Nukiwa(Tohoku University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Naoto Morikawa(Tohoku University), Koichi Okudera(Hirosaki Central Hospital), Akira Inoue(Tohoku University Hospital), Tomohiro Sakakibara(Tohoku University Hospital), Satoshi Oizumi(Hokkaido University), Yukihiro Hasegawa(Tokyo Metropolitan Children's Medical Center), Hajime Asahina(Hokkaido University), Shunichi Sugawara(Sendai Kousei Hospital), Kazuhiro Usui(Hokkaido University Hospital), Toshiro Suzuki(Sendai Kousei Hospital), Osamu Ishimoto(Sendai Kousei Hospital), Masao Harada(Shikoku Cancer Center), Ryota Saito(Tohoku University)
Cited by 3
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953